Sam Brusco, Associate Editor11.08.22
Leica Biosystems has acquired Cell IDx, a developer of multiplexed tissue profiling. Cell IDx provides multiplex staining panels, tissue staining, and imaging and analysis services.
The company’s UltraPlex allows simultaneous detection of multiple biomarkers in many immunoassays via fluorescent and chromogenic multiplex immunohistochemistry (IHC) staining technology and automated chromogenic detection of multiple markers on Leica’s BOND RX fully automated research stainer.
Together, the two technologies lets researchers detect three or more markers chromogenically on a single slide, with a straightforward pathology workflow.
"We are thrilled to welcome Cell IDx to the Leica Biosystems team," Gustavo Perez-Fernandez, president of Leica Biosystems told the press. "This acquisition will expand our capabilities in the translational research segment and help researchers to accelerate their journey, transforming scientific exploration into translational outcomes."
"The ability to differentiate multiple targets in brightfield has been a long-standing unmet need in clinical pathology. Multiplex chromogenic IHC allows the pathologist to, for example, detect targets inside and outside the tumor. This data on a single tissue section has the potential to inform real time therapy decisions and produce a more focused patient centric approach," said David Schwartz, co-founder and former CEO of Cell IDx. "Getting this technology into the hands of researchers will advance the science of cancer diagnostics and improve lives. We are delighted to be a part of this mission."
Robert Monroe, chief medical officer at Leica Biosystems, agreed with Schwartz on the value of UltraPlex. "The Cell IDx technology promotes the translation of complex multiplex IHC signatures into manageable three and four biomarker panels that can be automated on Leica Biosystems' BOND RX platform for high quality, reproducible staining," he said. "We see the pairing of UltraPlex and BOND automation as a platform for the creation of next generation tissue-based diagnostics for better prediction of therapeutic response and tumor behavior."
The company’s UltraPlex allows simultaneous detection of multiple biomarkers in many immunoassays via fluorescent and chromogenic multiplex immunohistochemistry (IHC) staining technology and automated chromogenic detection of multiple markers on Leica’s BOND RX fully automated research stainer.
Together, the two technologies lets researchers detect three or more markers chromogenically on a single slide, with a straightforward pathology workflow.
"We are thrilled to welcome Cell IDx to the Leica Biosystems team," Gustavo Perez-Fernandez, president of Leica Biosystems told the press. "This acquisition will expand our capabilities in the translational research segment and help researchers to accelerate their journey, transforming scientific exploration into translational outcomes."
"The ability to differentiate multiple targets in brightfield has been a long-standing unmet need in clinical pathology. Multiplex chromogenic IHC allows the pathologist to, for example, detect targets inside and outside the tumor. This data on a single tissue section has the potential to inform real time therapy decisions and produce a more focused patient centric approach," said David Schwartz, co-founder and former CEO of Cell IDx. "Getting this technology into the hands of researchers will advance the science of cancer diagnostics and improve lives. We are delighted to be a part of this mission."
Robert Monroe, chief medical officer at Leica Biosystems, agreed with Schwartz on the value of UltraPlex. "The Cell IDx technology promotes the translation of complex multiplex IHC signatures into manageable three and four biomarker panels that can be automated on Leica Biosystems' BOND RX platform for high quality, reproducible staining," he said. "We see the pairing of UltraPlex and BOND automation as a platform for the creation of next generation tissue-based diagnostics for better prediction of therapeutic response and tumor behavior."